Is VERA a good stock to buy? We came across a bullish thesis on Vera Therapeutics, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on VERA. Vera Therapeutics, Inc.’s share was trading at $42.91 as of June 30th.
Likoper/Shutterstock.com
Vera Therapeutics (VERA) is positioned as a late-stage biotechnology company with a focused pipeline targeting serious autoimmune and kidney diseases, with its lead asset atacicept forming the core of the investment thesis ahead of a major FDA PDUFA decision on July 7, 2026.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The market is currently undervaluing the company despite strong clinical evidence from the Phase 2b and Phase 3 ORIGIN trials, which demonstrated meaningful reductions in proteinuria of up to 46% alongside sustained immunologic suppression, reinforcing atacicept’s differentiated dual-pathway mechanism through BLyS and APRIL inhibition.
This mechanism is viewed as structurally superior to single-target competitors because it more effectively disrupts the survival of pathogenic antibody-producing cells driving IgA nephropathy progression. The near-term catalyst is the FDA accelerated approval decision, followed closely by critical Phase 3 eGFR kidney function data in Q3 2026, which could further validate long-term renal protection and significantly de-risk the asset for full approval and commercialization.
The bull case is strengthened by Vera’s strong liquidity position of $596.8 million in cash with no debt, providing a runway into late 2027 and allowing it to advance both atacicept and the optionality-rich MAU868 BK virus program without immediate financial distress. While concerns around cash burn exist, the company’s pipeline diversification and upcoming regulatory milestones provide multiple pathways for value creation, particularly if atacicept successfully transitions into broader rare kidney disease indications beyond IgA nephropathy.
In a risk-adjusted framework incorporating both assets, Vera is projected to deliver approximately 77% upside to a $74.00 price target, reflecting a meaningful re-rating opportunity if clinical and regulatory execution remains intact. The investment thesis ultimately hinges on successful FDA approval, strong confirmatory renal outcomes, and continued pipeline progress, which together could re-rate Vera from a clinical-stage biotech into a commercial-stage renal therapeutics platform with significant long-term upside potential.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy commercialization, strong gene-editing pipeline, and reimbursement-driven growth outlook. CRSP’s stock price has appreciated by approximately 33.12% since our coverage. BioEquity Watch shares a similar view but emphasizes Vera Therapeutics’ late-stage IgA nephropathy catalyst and near-term FDA PDUFA-driven re-rating potential.
Vera Therapeutics, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 56 hedge fund portfolios held VERA at the end of the first quarter which was 53 in the previous quarter. While we acknowledge the risk and potential of VERA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VERA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
